Abstract
B-type natriuretic peptide (BNP), initially identified in brain tissues, is now recognized as a key cardiac hormone. Numerous studies over the last decade have demonstrated that both exogenous and endogenous BNP prevent left ventricular (LV) hypertrophy in experimental settings, largely via activation of particulate guanylyl cyclase (pGC)-coupled receptors. BNP represents somewhat of a paradox, in that upregulation of BNP expression is widely used as a diagnostic marker for LV hypertrophy, diastolic dysfunction and heart failure in the clinic. We and others have postulated that BNP serves as an endogenous brake on the LV myocardium, seeking to curb the runaway train of signaling pathways that drive the progression from LV hypertrophy though remodeling, heart failure and death. This review summarizes the mechanisms of BNPs antihypertrophic actions, the role for cyclic GMP-mediated inhibition of pro-hypertrophic signaling, and BNPs impact on LV function. The improved understanding of the mechanisms of BNP regulation of LV hypertrophy and function that has emerged from both the experimental and clinical experience with this peptide provides new insight into the potential that BNP pharmacotherapy still offers for patients with LV hypertrophy.
Keywords: BNP, cardiomyocyte, cyclic GMP, hypertrophy, natriuretic peptides, nesiritide
Current Molecular Medicine
Title: B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Volume: 9 Issue: 7
Author(s): Rebecca H. Ritchie, Anke C. Rosenkranz and David M. Kaye
Affiliation:
Keywords: BNP, cardiomyocyte, cyclic GMP, hypertrophy, natriuretic peptides, nesiritide
Abstract: B-type natriuretic peptide (BNP), initially identified in brain tissues, is now recognized as a key cardiac hormone. Numerous studies over the last decade have demonstrated that both exogenous and endogenous BNP prevent left ventricular (LV) hypertrophy in experimental settings, largely via activation of particulate guanylyl cyclase (pGC)-coupled receptors. BNP represents somewhat of a paradox, in that upregulation of BNP expression is widely used as a diagnostic marker for LV hypertrophy, diastolic dysfunction and heart failure in the clinic. We and others have postulated that BNP serves as an endogenous brake on the LV myocardium, seeking to curb the runaway train of signaling pathways that drive the progression from LV hypertrophy though remodeling, heart failure and death. This review summarizes the mechanisms of BNPs antihypertrophic actions, the role for cyclic GMP-mediated inhibition of pro-hypertrophic signaling, and BNPs impact on LV function. The improved understanding of the mechanisms of BNP regulation of LV hypertrophy and function that has emerged from both the experimental and clinical experience with this peptide provides new insight into the potential that BNP pharmacotherapy still offers for patients with LV hypertrophy.
Export Options
About this article
Cite this article as:
Ritchie H. Rebecca, Rosenkranz C. Anke and Kaye M. David, B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target, Current Molecular Medicine 2009; 9 (7) . https://dx.doi.org/10.2174/156652409789105499
DOI https://dx.doi.org/10.2174/156652409789105499 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bio-Active Chemical Constituents from the Genus Streptocaulon
Mini-Reviews in Organic Chemistry Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Sarcopenia, Cachexia and Congestive Heart Failure in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Antisense DNA and RNA: Potential Therapeutics for Viral Infection
Anti-Infective Agents in Medicinal Chemistry Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Current Drug Targets Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications
Current Molecular Medicine Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun
Current Pharmaceutical Design Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Tetraspanins-Structural and Signalling Scaffolds that Regulate Platelet Function
Mini-Reviews in Medicinal Chemistry The Future of Collateral Artery Research
Current Cardiology Reviews